• Regenxbio scheduled webcast for May 14, 2026 at 8:00 a.m. ET to discuss topline results from pivotal RGX-202 Duchenne muscular dystrophy trial.
• First-quarter 2026 financial results slated for release premarket May 14, 2026, ahead of webcast; access via https://www.regenxbio.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605060705PR_NEWS_USPR_____PH52422) on May 06, 2026, and is solely responsible for the information contained therein.